163RC, Scientist, Cancer Immunotherapy

Scientist, Cancer Immunotherapy
Job Code 163RC

Description
Fate’s Cancer Immunotherapy group is seeking an experienced and highly motivated cell biologist with expertise in T cell immunology and developmental biology to join a multidisciplinary team dedicated to the discovery of novel off-the-shelf cellular therapeutics for the treatment of cancer and other disorders. The successful candidate will be responsible for optimization and execution of novel T and CAR-T lymphoid differentiation protocols from induced pluripotent stem cells (iPSC), their subsequent scale-up and application to therapeutic indications. In addition, the candidate will be responsible for the functional assessment of iPSC-derived T and CAR-T cells in both in vitro and in vivo models. The candidate must have in depth knowledge of T cell immunology in addition to extensive experience with mammalian cell culture. The position will require individual, independent research as well as coordination with the reprogramming biology and engineering, immunology, in vivo biology and process development groups. This is a full-time position reporting to the Senior Scientist, Cancer Immunotherapy, and is located at our corporate headquarters in San Diego, CA.

Download a PDF of the job description for more details:
pdf version163RC, Scientist, Cancer Immunotherapy

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 163RC.

About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.